meglumine has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunton, T; Evans, A; Henderson, SA; Jordan, LB; Muhammad Gowdh, N; Purdie, CA; Thompson, AM; Vinnicombe, S | 1 |
| Buckley, DL; Dall, BJ; Dodwell, D; Farrow, IM; Georgiou, L; Hanby, AM; Hughes, TA; Perren, TJ; Sharma, N; Stevens, W; Wilson, DJ; Windel, LM | 1 |
2 other study(ies) available for meglumine and docetaxel anhydrous
| Article | Year |
|---|---|
Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Meglumine; Middle Aged; Neoadjuvant Therapy; Organometallic Compounds; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden | 2018 |
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Meglumine; Middle Aged; Neoadjuvant Therapy; Organometallic Compounds; Predictive Value of Tests; Prospective Studies; Trastuzumab; Tumor Burden | 2021 |